CD8A and neoplasm: In addition, significantly more mice survived up to 30 days after the injection of B16-OVA tumor cells that received the A1-gene transduced OX40 KO CD8 T cells compared to control vector-transduced OX40 KO CD8 T cells (16.7% vs 66.7%; P<0.05, log rank test), and survival was similar to mice receiving the vector-transduced WT CD8 T cells (Fig. 7b).